Hangzhou Dian Zhengjian Testing Technology Co., Ltd. announced that it expects to receive CNY 40 million in funding from Zhejiang DIAN Diagnostics Co., Ltd.
April 12, 2016
Share
Hangzhou Dian Zhengjian Testing Technology Co., Ltd. announced that it will receive CNY 40,000,000 in a round of equity funding from existing investor Zhejiang DIAN Diagnostics Co., Ltd. on April 12, 2016. Post the closing of the transaction; the investor will maintain its stake of 100% in the company's issued and outstanding share capital for a total amount of CNY 50,000,000. The transaction has been approved at the 52nd session of the 2nd directorate of the investor.
Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.
Hangzhou Dian Zhengjian Testing Technology Co., Ltd. announced that it expects to receive CNY 40 million in funding from Zhejiang DIAN Diagnostics Co., Ltd.